Klin Farmakol Farm. 2014;28(2):72-79

Carelink, Diabass 5.

Rudolf Chlup1,2,3, Ondřej Krystyník1, Michaela Nádvorníková3, Hana Zálešáková3, Emilia Ďurajková3, Iveta Poljaková2, Pavla Kudlová4, Josef Bartek5, Jana Zapletalová6, Vlastimil Procházka1
1 II. interní klinika Lékařské fakulty Univerzity Palackého v Olomouci a Fakultní nemocnice Olomouc
2 Ústav fyziologie Lékařské fakulty Univerzity Palackého v Olomouci
3 Odborný léčebný ústav neurologicko-geriatrický Moravský Beroun
4 Ústav zdravotnických věd Fakulty humanitních studií Univerzity Tomáše Bati ve Zlíně
5 Ústav lékařské chemie a biochemie Lékařské fakulty Univerzity Palackého v Olomouci
6 Ústav lékařské biofyziky Lékařské fakulty Univerzity Palackého v Olomouci

Ten-point glycaemic profile: a flexible indicator of therapeutic efficacy and dawn phenomenon in persons with type 1

or type 2 diabetes mellitus

This overview has summarized the authors' experience with intensive selfmonitoring including an evaluation of glucometers' reliability.

A ten-point glycaemic profile and continuous monitoring are flexible indicators of therapeutic effectiveness and the dawn

phenomenon in persons with type 1 or type 2 diabetes mellitus. A personal glucometer, selfmonitoring and education are now becoming

prerequisites for successful intensive insulin treatment particularly when using the insulin pump. These modern methods

should be implemented into practice. The following types of glucometers have been subsequently tested at the authors' workplaces:

One Touch (Lifescan, GB), Optium (Medisense/Abbott, GB), Card (Medisense/Abbott, GB), Advance (Hypoguard, GB), Linus (Agamatrix,

USA), Contourlink (Bayer, BRD) a CALLA (Wellion, Austria). Accuracy andrepeatability of results oéf tested glucometers allow their

implementation into practice.

Carelink, Diabass 5.

Keywords: diabetes mellitus, dawn phenomenon, selfmonitoring, glycaemic profile, glucometer, insulin pumps, therapeutic education,

Published: July 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Chlup R, Krystyník O, Nádvorníková M, Zálešáková H, Ďurajková E, Poljaková I, et al.. Carelink, Diabass 5. Klin Farmakol Farm. 2014;28(2):72-79.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Poljakova I, Elsikova E, Chlup R, Kalabus S, Hasala P, Zapletalova J. Glucose sensing module - Is it time to integrate it into real-time perioperative monitoring? An observational pilot study with subcutaneous sensors. Biomedical Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013; 157(4): 346-357. Go to original source... Go to PubMed...
    2. Česká diabetologická společnost: Doporučený postup péče o nemocné s diabetes mellitus 1. typu. Diabetes, endokrinologie, metabolismus, výživa 2012; 1: 8-12.
    3. Česká diabetologická společnost: Doporučený postup péče o nemocné s diabetes mellitus 2. typu. Diabetes, endokrinologie, metabolismus, výživa 2012; 1: 13-19.
    4. Česká diabetologická společnost: Doporučený postup péče o nemocné s prediabetem. Diabetes, endokrinologie, metabolismus, výživa 2012; 1: 20-22.
    5. Kohnert KD, Augstein P, Heinke P, Zander E, Peterson K, Freyse EJ, Salzsieder E. Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetes. Diabetes Research and Clinical Practice 2007; 77: 420-426. Go to original source... Go to PubMed...
    6. Kohnert KD, Augstein P, Zander E, Heinke P, Peterson K, Freyse EJ, Hovorka R, Salzsieder E. Glycemic variability correlates strongly with postprandial ?-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 2009; 32(6): 1058-1062. Go to original source... Go to PubMed...
    7. Miller KM, Beck RW, Bergenstal RM, Goland RS, Haller MJ, McGill JB, Rodriguez H, Simmons JH, Hirsch IB. T1D Exchange Clinic Network: Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1C levels in T1D Exchange Clinic Registry participants. Diabetes Care 2013 February 1 [Epub ahead of print]. Go to original source...
    8. Langova K, Pribylova H, Kajabova M, Luza J. Assessment of haemoglobin a1c evolution using two statistical approaches (survival analysis and linear regression) in persons with diabetes mellitus. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009; 153(2): 137-144. Go to original source... Go to PubMed...
    9. Peterson K, Zapletalova J, Kudlova P, Matuskova V, Bartek J, Novotny D, Chlup R. Benefits of three-month continuous glucose monitoring for persons with diabetes using insulin pumps and sensors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009; 153(1): 47-52. Go to original source... Go to PubMed...
    10. Mazze R, Lucido D, Langer O, Hartmann K, Rodbard D. Ambulatory glucose profile: representation of verified self-monitored blood glucose data. Diabetes Care 1987; 10: 111-117. Go to original source... Go to PubMed...
    11. Bergenstal RM, Ahmann AJ, Bailey T, Beck RW, Bissen J, Buckingham B, Deeb L, Dolin RH, Garg SK, Goland R, Hirsch IB, Klonoff DC, Kruger DF, Matfin G, Mazze RS, Olson BA, Parkin C, Peters A, Powers MA, Rodriguez H, Southerland P, Strock ES, Tamborlane W, Wesley DM. Recommendations for standardizing glucose reporting and analysis to optimizme clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther 2013; 15: 198-211. Go to original source... Go to PubMed...
    12. Garg SK, Hirsch IB. Self-Monitoring of Blood Glucose An Overview. Diabetes Technology & Therapeutics 2013; 15(Suppl 1): S3-S12. Go to original source... Go to PubMed...
    13. Hirsch IB, Amiel SA, Blumer IR, Bode BW, Edelman SV, Seley JJ, Verderese CA, Kilpatrick ES. Using multiple measures of glycemia to support individualized diabetes management: recommendations for clinicians, patients, and payers. Diabetes Technol Ther 2012; 11: 973-983. Go to original source... Go to PubMed...
    14. Berger M, Jörgens V, Chlup R. Léčba inzulinem v každodenním životě. Ed. 1. Victoria Publishing, Praha, 1995.
    15. Bibergeil H Ed. Diabetes mellitus - ein Nachschlagewerk für die diabetologische Praxis. Edition 3, 1988, VEB Gustav Fischer Verlag Jena.
    16. Bruns W, Fiedler H, Altman B, Lundershausen R, Menzel R, Worms F, Kriegstein E. Insulintherapie bei Typ 2 Diabetes Pathophysiologisch begründete Therapie mitz insulin unter besonderer Berücksichtigung der Insulinresistenz und des Inkretineffektes. 2. Auflage-Bremen. Germany, UNIMED Verlag AG, 2010.
    17. Chlup R, Gazárek F, Krikal Z, Flasarová B. Diabetes mellitus a tehotenstvi [Diabetes mellitus and gravidity (author's transl)][Article in Czech]. Cesk Gynekol. 1976; 41(2): 113-115. PMID: 1268961. Go to PubMed...
    18. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. Brit Med J 2011; 343: d3805. Go to original source... Go to PubMed...
    19. Chlup R, Možíšová L. Léčba diabetiků pomocí inzulinové pumpy - teorie a praxe. Diabetologie Metabolismus Endokrinologie Výživa 2000; 3(1): 3-17.
    20. Chlup R, Janů K, Menzel R, Bruns W, Venháčová J. Léčba diabetu pomocí ručního dávkovače inzulinu MADI. Ed. Univerzita Palackého v Olomouci, 1985.
    21. Chlup R, Janu K, Venhacova J, Bartek J. Six models of a new insulin pen (MADI): Description and first clinical trial. Practical Diabetes International 1995; 12(1): 32-35. Go to original source...
    22. Bruns W. Insulin therapy in obese patients with type 2 diabetes [Insulintherapie des adiposen typ-2-diabetes]. Diabetes und Stoffwechsel 1999; 8(SUPPL 6): 26-31.
    23. Bruns, W, Jutzi E, Fischer U, Bombor H, Woltanski KP, Jahr D, Wodrig W, Albrecht G. Circadian variations in insulin concentrations and blood glucose in non-diabetics as well as insulin requirements in insulin-dependent diabetics. [Uber tagesrhythmische Veränderungen der Insulinkonzentrationen und der Plasmaglukose bei Nichtdiabetikern sowie des Insulinbedarfs bei insulinpflichtigen Diabetikern.] Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete 1981; 36(5): 258-260. Go to PubMed...
    24. Chlup R, Menzel R, Keilacker H, Heinke P, Jutzi E. Night injections of regular insulin improve diabetes control in C-peptide negative patients. Diabetologia 1997; 40(Suppl): 1292-1292 (Abstract). Go to PubMed...
    25. Chlup R, Vaverkova H, Bartek J. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. I. Effects on blood glucose control. Exp Clin Endocrinol Diabetes 1997; 105(Suppl 2): 70-73. Go to original source... Go to PubMed...
    26. Chlup R, Zapletalová J, Seckar P, Chlupová L, Táncosová S, Reznícková M. Benefits of insulin aspart vs phosphate-buffered human regular insulin in persons with type 1 Diabetes treated by means of an insulin pump. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004; 148(1): 27-32. Go to original source... Go to PubMed...
    27. Chlup R, Zapletalová J, Seckar P, Malá E, Doubravová B, Táncosová S, Chlupová L, Pukowietz L, Zatloukal P. Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus. Diabetes Technol Ther. 2007; 9(3): 223-231. Go to original source... Go to PubMed...
    28. Chlup R, Zapletalová J, Sečkař P, Chlupová L, Táncosová S, Řezníčková M. Benefits of insulin aspart vs phosphate-buffered human regular insulin in persons with type 1 diabetes treated by means of an insulin pump. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004; 148(1): 27-32. Go to original source... Go to PubMed...
    29. Chlup R, Navrátilová L, Řehořová J, Vaverková H, Venháčová J, Bartek J, Ficker L, Slezáková L. Programová léčba diabetu. Ed. 1, 1996, Galén, Praha.
    30. Chlup R, Doubravova B, Bartek J, Zapletalova J, Krystynik O, Prochazka V. Effective Assessment of Diabetes Control Using Personal Glucometers (CONTOURLINK, Bayer, Germany; CALLA, Wellion, Austria; LINUS, Agamatrix, USA). Disease Markers 2013; 35(6): 895-905. Go to original source... Go to PubMed...
    31. Kudlová P, Chlup R. Selfmonitoring u osob s diabetem. Interní Medicina pro Praxi 2009; 11(Suppl B): B66-B71.
    32. Chlup R, Beránková I, Boudová E, Ďurajková E, Faltýnková J, Fišarová S, Gajdošová M, Grecmanová M, Holá J, Holešinská P, Hrubá V, Kmoníčková A, Konštacká L, Pevná Z, Řehořová J, Strnadová J, Šeflová L. Doporučení pro léčbu inzulinem u dospělých diabetiků při hospitalizaci - návrh standardu. Klin Farmakol Farm 2003; 17(1): 34-42.
    33. ISO 15197 In Vitro Diagnostic Test Systems-Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. ISO 15197: 2003(E). Geneva: International Standards Organization, 2003.
    34. ISO/DIS 15197 In Vitro Diagnostic Test Systems-Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. ISO/DIS 15197: 2013. Geneva: International Standards Organization, 2013.
    35. Thorpe GH. Assessing the quality of publications evaluating the accuracy of blood glucose monitoring systems. Diabetes Technology & Therapeutics. 2013; 15(3): 253-259. Go to original source... Go to PubMed...
    36. Freckmann G, Schmid C, Baumstark A, Pleus S, Link M, Haug C. System accuracy evaluation of 43 blood glucose monitoring systems for self-monitoring of blood glucose according to DIN EN ISO 197. J Diabetes Sci Technol 2012; 6(5): 1060-1075. Go to original source... Go to PubMed...
    37. Chlup R, Bartek J, Malá E, Doubravová B, Pukowietz L, Zatloukal P, Chlupová L, Zapletalová J. Uživatelská studie o správnosti a přesnosti měření glukometrů Advance, Card a Optium (User oriented study on accuracy and precision of glucometer systems Advance, Card and Optium). Klin Bioch Metabol 2004; 12(3): 171-178.
    38. Chlup R, Bartek J, Zapletalová J, Sečkař P, Pukowietz L, Řezníčková M, Havrdová M, Rulfová L. Výsledky měření P-glukosy na glukometrech Advance a Optium v laboratorních podmínkách (Results of P-glucose estimations by means of glucometers Advance and Optium under laboratory conditions). Klin Bioch Met 2004; 12(3): 160-170.
    39. Chlup R, Payne M, Zapletalová J, Komenda S, Doubravová B, Reznícková M, Chlupová L, Seckar P. Results of selfmonitoring on glucometer systems Advance and Optium in daily routine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005; 149(1): 127-139. Go to original source... Go to PubMed...
    40. Chlup R, Doubravova B, Peterson K, Zapletalova J, Bartek J. Wavesense technology glucometer Linus for routine self-monitoring and clinical practice. Acta Diabetol 2011; 48(1): 35-40. Go to original source... Go to PubMed...
    41. Chlup R, Doubravova B, Zapletalova J, Peterson K, Bartek J. Plasma glucose concentrations on new glucometer CALLA strongly correlate with laboratory analyser COBAS INTEGRA 400 PLUS under various clinical conditions. Diabetes Technol Ther 2011; 13(2): 213-214 (Abstract).
    42. Chlup R, Doubravova B, Zapletalova J, Langova K, Bartek J. Glucometers (CALLA) appear to be more convenient means for routine P-glucose monitoring in patients admitted to hospital than a laboratory analyzer (COBAS INTEGRA). Diabetes Technol Ther 2011; 13(2): 214-215 (Abstract).
    43. Mlčák P, Chlup R, Boudová E, Bartek J, Zapletalová J. Assessment of glucose concentrations in intersticial fluid in non-diabetic subjects with regard to detection of the dawn phenomenon - Pilot study. [Vývoj koncentrace glukosy v intersticiální tekutině u nediabetiků s ohledem na detekci fenoménu svítání - Pilotní studie]. Klin Bioch Metabol 2003; 11(1): 44-49.
    44. Mlcak P, Fialová J, Trnková K, Chlup R. A continuous glucose monitoring system (CGMS) - a promising aproach for improving metabolic control in persons with type 1 diabetes mellitus treated by insulin pumps. Biomed Pap Med Fac Univ Palacky Olomouc, Czech Repub. 2004; 148: 33-38. Go to original source... Go to PubMed...
    45. Rodbard D, Bailey T, Jovanovic L, Zisser H, Kaplan R, Garg SK. Improved quality of glycemic control and reduced glycemic variability with use of continuous glucose monitoring. Diabetes Technol Ther 2009; 11: 717-723. Go to original source... Go to PubMed...
    46. Battelino T, Conget I, Olsen B, Schütz-Fuhrmann I, Hommel E, Hoogma R, Schierloh U, Sulli N, Bolinder J. the SWITCH Study Group: The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012; 55: 3155-3162. Go to original source... Go to PubMed...
    47. Damiano ER, El-Khatip FH, Zheng H, Nathan DD, Russell SJ. A comparative effectiveness analysis of three continuous glucose monitors. Diabetes Care 2013; 36: 251-259. Go to original source... Go to PubMed...
    48. Jadviscokova T, Fajkusova Z, Pallayova M, Luza J, Kuzmina G. Occurence of adverse events due to continuous glucose monitoring. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007; 151(2): 263-266. Go to original source... Go to PubMed...
    49. Chlup R, Mlčák P, Boudová E, Fialová J, Barker J. Continuous glucose monitoring in interstitial fluid - Initial experience [Kontinuální monitorování koncentrace glukosy v intersticiální tekutině - naše první zkušenosti]. Klin Bioch Metabol 2003; 11(1): 37-43.
    50. Chlup R, Jelenova D, Kudlova P, Chlupova K, Bartek J, Zapletalova J, Langova K, Chlupova L. Continuous glucose monitoring - a novel approach to the determination of the glycaemic index of foods (DEGIF 1). Exp Clin Endocrinol Diabetes 2006; 114: 68-74. Go to original source... Go to PubMed...
    51. Liebl A, Henrichs HR, Heinemann L, Freckmann G, Biermann E, Thomas A. Continuous Glucose Monitoring Working Group of the Working Group Diabetes Technology of the German Diabetes Association. Continuous glucose monitoring: evidence and consensus statement for clinical use. J Diabetes Sci Technol. 2013; 7(2): 500-519. PubMed PMID: 23567009. Go to original source... Go to PubMed...
    52. Peterson K, Chlup R, Zapletalova J, Kohnert KD, Kudlova P, Bartek J, Nakladalova M, Doubravova B, Seckar P. Influence of oral antidiabetic drugs on hyperglycemic response to foods in persons with type 2 diabetes mellitus as assessed by continuous glucose monitoring system: a pilot study. J Diabetes Sci Technol 2010; 4(4): 983-992. Go to original source... Go to PubMed...
    53. Bruttomesso D, Costa S, Baritussio A. Continuous subcutaneous insulin infusion (CSII) 30 years later: Still the best option for insulin therapy (Review). Diabetes/Metabolism Research and Reviews 2009; 25(2): 99-111. Go to original source... Go to PubMed...
    54. Cohen O, Körner A, Chlup R, Zoupas CS, Ragozin AK, Wudi K, Bartaskova D, Pappas A, Niederland T, Taybani Z, Barák L, Vazeou A. Improved glycemic control through continuous glucose sensor-augmented insulin pump therapy: Prospective results from a community and academic practice patient registry. Journal of Diabetes Science and Technology 2009; 3(4): 804-811. Go to original source... Go to PubMed...
    55. Jankovec Z, Hahn M, Grunder S, Lacigova S, Cechurova D, Krcma M, Zourek M, Haladova I, Rusavy Z. Analysis of continuous patient data from the Czech National Register of patients with type 1 and type 2 diabetes using insulin pump therapy.Diabetes Research and Clinical Practice 2010; 87(2): 219-223. Go to original source... Go to PubMed...
    56. Jankovec Z, Krcma M, Gruberova J, Komorousova J, Tomesova J, Zourek M, Rusavy Z. Influence of physical activity on metabolic state within a 3h interruption of continuous subcutaneous insulin infusion in patients with type 1 diabetes. Diabetes Technology and Therapeutics 2011; 13(12): 1234-1239. Go to original source... Go to PubMed...
    57. Jankovec Z. Options of treatment with insulin pumps (Review) [Možnosti léčby inzulinovými pumpami]. Interni Medicina pro Praxi 2012; 14(3): 116-118.
    58. Lippaiova N, Pallayova M, Kuzmina G, Peterson K, Fajkosova L, Luza J. Safety of new algorithms for premeal insulin boluses in high glycaemic index meals in persons with type 1 diabetes mellitus using insulin pumps. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008; 152(1): 73-77. Go to original source... Go to PubMed...
    59. Chlup R, Tomcalova J, Kudlova P, Zapletalova J. Pump away: patients' rejection of continuous subcutaneous insulin infusion, physician's decision to switching to other treatments and death rates. Diabetes Technology & Therapeutics 2013; 15(Suppl 1): A37-A37.
    60. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.